Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401369 | 1.00 | KMT2A (0.67) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL29679073 | 1.00 | KMT2A (0.67) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL10052316 | 1.00 | KMT2A (0.67) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL13160289 | 1.00 | KMT2A (0.67) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL29398504 | 1.00 | KMT2A (0.67) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL29401202 | 1.00 | KMT2A (0.67) | KMT2ADPP8DPP7EPHX2ANPEP | |
| Hydrochloric Acid SCHEMBL28633717 | 0.99 | KMT2A (0.66) | KMT2ADPP8DPP7EPHX2ANPEP | |
| Hydrochloric Acid SCHEMBL29401551 | 0.99 | KMT2A (0.66) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL31453877 | 0.99 | KMT2A (0.66) | KMT2ADPP8DPP7EPHX2ANPEP | |
| SCHEMBL17746951 | 0.96 | KMT2A (0.65) | KMT2ADPP8DPP7EPHX2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863265-B2 | 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
| EP-1896408-A1 | NEW 2-AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDAEMIC DISEASES | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896407-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137782-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006137794-A1 | NEW2-AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDAEMIC DISEASES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216759-A1 | Novel 2-Azetidinone Derivatives And Their Use As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemia | CYP46A1, NPC1L1, LIPA | KMT2A 2756/4885DPP8 313/4885DPP7 200/4885 |
| US-20100152156-A1 | 2-Azetidinone Derivatives For The Treatment Of Hyperlipidaemic Diseases | NPC1L1, CYP46A1, PCSK9 | KMT2A 1915/4885DPP8 411/4885DPP7 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.